Kagocel - instructions for use, doses, side effects, contraindications

Clinical and pharmacological group: & nbsp

Antiviral drugs

Included in the formulation

Kagocel®

pills inwards

NEARMEDIC PLUS, LLC Russia

Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

VED

ONLS

Minimal chemist's assortment

АТХ:

J.05.A.X Other antiviral drugs

Pharmacodynamics:

The main component of the mechanism of action is the ability to induce the production of interferon. Kagocel causes the formation in the human body of the so-called late interferon, which is a mixture of alpha and beta interferons with high antiviral activity. Kagocel causes the production of interferon in virtually all cell populations that participate in the antiviral response of the body: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells.

Pharmacokinetics:

When administered orally, about 20% of the administered dose of the drug enters the total blood flow. The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: 47% - with lipids, 37% - with proteins. The unbound portion of the drug is about 16%.

The interferon response of the body to the administration of kagocella is characterized by a prolonged (up to 4-5 days) circulation of interferon in the bloodstream. The dynamics of accumulation of interferon in the intestine when ingested kagocel does not coincide with the dynamics of circulating interferon titers.In the blood serum, interferon production reaches high values only 48 hours after the administration of kagocel, while in the intestine the maximum production of interferon is observed after 4 hours.

24 hours after the introduction into the body kagocel accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, lymph nodes. Low concentration is noted in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of kagocel in the brain is explained by the high molecular weight of the preparation, which hinders its penetration through blood-brain barrier. In blood plasma the preparation is mainly in a bound form.

Kagocel, when prescribed in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not have mutagenic and teratogenic properties, it is not carcinogenic and does not have an embryotoxic effect.

The greatest effectiveness in the treatment of kagocel is achieved with its appointment no later than the 4th day after the onset of acute infection. For preventive purposes, the drug can be used at any time, including and immediately after contact with the infectious agent.

Excretion: from the body the drug is excreted mainly through the intestine: 7 dayOK after administration - 88% of the administered dose, including 90% through the intestine and 10% by the kidneys. In the exhaled air the drug was not detected.

Indications:

- prevention and treatment of influenza and other acute respiratory viral infections in adults and children from the age of 3 years and older;

- Treatment of herpes in adults.

ICD-10

I.B00-B09.B00 Infections caused by the herpes simplex virus [herpes simplex]

X.J00-J06.J06.9 Acute upper respiratory tract infection, unspecified

X.J10-J18.J10 Influenza caused by an identified influenza virus

Contraindications:

- Pregnancy;

- the period of lactation (breastfeeding);

- Children's age up to 3 years;

- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

- Hypersensitivity to the components of the drug.

Carefully:

No data.

Pregnancy and lactation:

FDA Action Category not determined.

In connection with the lack of necessary clinical data kagocel not recommended for use during pregnancy and during breastfeeding.

Dosing and Administration:

Inside.

To treat influenza and acute respiratory viral infections adults prescribe 2 tablets 3 times a day for the first 2 days, in the next 2 days - 1 tablet 3 times a day. In total, the course of treatment - 18 tablets, the duration of the course - 4 days.

Prevention of influenza and acute respiratory viral infections in adults is carried out by 7-day cycles: 2 days 2 tablets 1 time per day, 5 days break, then repeat the cycle. The duration of the preventive course is from 1 weeks up to several months.

For the treatment of herpes in adults prescribe 2 tablets 3 times a day for 5 days. In total, the course of treatment - 30 tablets, the duration of the course - 5 days.

To treat influenza and acute respiratory viral infections children aged 3 to 6 years appoint 1 tablet 2 times a day for the first 2 days, in the next 2 days - 1 tablet 1 time per day. There are 6 tablets per course, and the duration of the course is 4 days.

To treat influenza and acute respiratory viral infections children aged 6 years appoint 1 tablet 3 times a day for the first 2 days, in the next 2 days - 1 tablet 2 times a day. In total, the course of treatment - 10 tablets, the duration of the course - 4 days.

Prevention of influenza and acute respiratory viral infections in children aged 3 years is carried out by 7-day cycles: 2 days 1 tablet 1 time per day, 5 days break, then repeat the cycle. The duration of the preventive course is from 1 weeks up to several months.

Side effects:

Perhaps the development of allergic reactions.

If any side effects are aggravated, tell your doctor about it.

Overdose:

In case of an accidental overdose, it is recommended that an abundant drink be prescribed, induction of vomiting.

Interaction:

With the simultaneous use of the drug with other antiviral drugs, immunomodulators and antibiotics, an additive effect is observed.

Special instructions:

To achieve a therapeutic effect, kagotsev should be taken no later than the 4th day after the onset of the disease.

Instructions

Kagocel (Kagocelum)